The GLP-1 receptor agonist has been available in the European Union since 2015 for the treatment of obesity in a maximum dose of 3.0 mg (in contrast, liraglutide 1.8 mg is used for the treatment of T2D). Here, GLP1R is linked to obesity disorder.